Neuroone Medical Technologies (NMTC) Long-Term Deferred Tax (2018 - 2025)

Neuroone Medical Technologies' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $20.6 million for Q3 2025.

• Quarterly Long-Term Deferred Tax rose 7.32% year-over-year to $20.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $20.6 million (up 7.32% YoY) and the FY2025 annual result came in at $20.6 million, up 7.32% from the prior year.
• Long-Term Deferred Tax was $20.6 million for Q3 2025 at Neuroone Medical Technologies, up from $19.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $20.6 million in Q3 2025 and bottomed at $8.9 million in Q3 2021.
• A 5-year average of $15.2 million and a median of $15.4 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax jumped 55.81% — and 2025, when it increased 7.32%.
• Neuroone Medical Technologies' Long-Term Deferred Tax stood at $8.9 million in 2021, then surged by 34.32% to $11.9 million in 2022, then rose by 29.45% to $15.4 million in 2023, then climbed by 24.22% to $19.2 million in 2024, then rose by 7.32% to $20.6 million in 2025.
• Business Quant data shows NMTC's Long-Term Deferred Tax at $20.6 million in Q3 2025, $19.2 million in Q3 2024, and $15.4 million in Q3 2023.